Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chromium picolinate→

Chromium picolinate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
14639-25-9
PubChem CID
151932
Molecular formula
C18H12CrN3O6
Molecular weight
418.3 g/mol
Drug class
Trivalent chromium (Cr3+) nutritional supplementchromium picolinate complex
Mechanism of action
Provides trivalent chromium, a trace element proposed to influence insulin signalling and macronutrient metabolism. The molecular role of chromium in humans is incompletely defined, and clinical evidence for glycaemic benefit is inconsistent.
Indications / reported uses
  • Nutritional supplementation in selected patients with inadequate chromium intake; use for diabetes or weight loss is not an established universally approved therapeutic indication

Sources: NIH Office of Dietary Supplements — Chromium fact sheet · NLM MeSH — Chromium picolinate · FDA product information

Identification source: PubChem record (CID 151932). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chromium picolinate Environmental Risk Assessment (ERA) (the Chromium picolinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.